地舒单抗与阿仑膦酸盐治疗骨质疏松症的药物经济学对比评价文献研究  

Pharmacoeconomic evaluation of denosumab and alendronate for the treatment of osteoporosis

作　　者：周瑾 杨晓姣 赵振宇[1] ZHOU Jin;YANG Xiao-jiao;ZHAO Zhen-yu(NHC Key Laboratory of Hormones and Development,Tianjin Key Laboratory of Metabolic Diseases,Chu Hsien-I Memorial Hospital&Tianjin Institute of Endocrinology,Tianjin Medical University,Tianjin 300134,China)

机构地区：[1]天津医科大学朱宪彝纪念医院,天津市内分泌研究所,国家卫健委激素与发育重点实验室,天津市代谢性疾病重点实验室,天津300134

出　　处：《现代药物与临床》2022年第11期2635-2640,共6页Drugs & Clinic

摘　　要：目的 对比评价地舒单抗与阿仑膦酸盐用于骨质疏松症治疗的药物经济学研究结果,为骨质疏松的临床用药治疗决策提供参考。方法:以“骨质疏松”“地舒单抗”“阿仑膦酸盐”“成本效果”“成本效益”“成本效用”“经济性分析”“药物经济学”为中文检索词,以“osteoporosis”“denosumab”“alendronate”“cost-effectiveness”“cost-utility”“cost-benefit”“economicanalysis”“pharmacoeconomics”为英文检索词,在中国知网、万方数据、维普网、PubMed、Web of Science、EMBASE等数据库中检索2000年1月1日-2022年10月20日公开发表的地舒单抗的药物经济学评价文献,按照纳入与排除标准筛选文献后,提取相关信息,使用卫生经济学评价报告标准共识量表对纳入文献进行质量评价,从文献基本信息、文献质量、模型结构及要素、健康状态及效用值、成本项目和来源、健康产出、经济学评价、敏感性分析等对地舒单抗治疗骨质疏松的药物经济学评价方法和结果进行描述性统计分析。结果 共纳入6篇文献,文献总符合率均在80.00%以上。地舒单抗对比阿仑膦酸盐治疗骨质疏松的药物经济学评价研究主要采用马尔可夫模型,模型结构较为成熟;成本确认的范围应与所选的角度一致,包括直接成本、间接成本、隐形成本;效果值多源于已有文献的随机对照试验系统评价或荟萃分析;敏感性分析采用确定性敏感性分析和概率敏感性分析,主要影响因素为成本。结论 地舒单抗在我国上市不久,本研究可为临床骨质疏松的治疗提供新的思路,更规范地开展相关药物经济学评价研究。Abjective: Objective To compare the pharmacologic results of diuzumab and alendronate for osteoporosis treatment and to provide reference for clinical treatment decisions of osteoporosis. Methods Take “osteoporosis”“denosumab”“alendronate”“cost-effect” “cost-utility” “cost-benefit”“economic analysis”“drug economics” as the Chinese search term, “osteoporosis”“denosumab” “alendronate” “cost-effectiveness”“cost-utility”“cost-benefit”“economic analysis”“pharmacoeconomics” as English, the pharmaceconomic evaluation literature of denosumab was publicly published from January 1, 2000 to October 20, 2022 in CNKI, Wan-Fang Data, VipNet, PubMed, Web of Science, EMBASE. After literature screening according to inclusion and exclusion criteria, relevant information was extracted, and the quality of the included literature was evaluated using the standard consensus scale of the health economics evaluation report. The pharmacoeconomic evaluation methods and results of denosumab in the treatment of osteoporosis were analyzed from the basic information of literature, literature quality, model structure and elements, health status and utility value, cost items and sources, health output, economic evaluation and sensitivity analysis. Results A total of 6 literatures were included, and the total coincidence rate was above 80.00%. The pharmacoeconomic evaluation of denosumab versus alendronate in the treatment of osteoporosis mainly used Markov model, and the model structure is relatively mature. The scope of cost recognition should be consistent with the selected Angle, including direct cost, indirect cost and hidden cost. The effect values were mostly from systematic reviews or meta-analyses of randomized controlled trials with existing literatures. Sensitivity analysis adopts deterministic sensitivity analysis and probabilistic sensitivity analysis, and the main influencing factor is cost. Conclusion Shortly after the listing of denosumab, this study could provide a n

关 键 词：地舒单抗 阿仑膦酸盐 骨质疏松 药物经济学评价 文献研究 

分 类 号：R982[医药卫生—药品]